Skip to main content
How do I know if I have the BRAF V600E mutation?
BRAF test icon

Biomarker testing is a key step in finding out if your cancer is caused by a mutation like the BRAF V600E mutation. If your tumor tissue tests positive for the BRAF V600E mutation, your health care provider may prescribe a treatment specific for your cancer like TAFINLAR + MEKINIST.

How BRAF V600E mutation testing works

Who can request it: BRAF V600E genetic mutations can only be detected through a specific biomarker test ordered by your health care provider.
How to request it: Even if you’ve had testing done before, you’ll need to ask specifically for a comprehensive biomarker test for the BRAF V600E genetic mutations.
How the test is performed: BRAF V600E genetic mutations can be detected in tissue samples. Your health care provider will send a tissue sample to a lab for the test. If you’ve had a biopsy done before, ask your health care provider if your tissue is still available for BRAF V600E biomarker testing.

Ask your health care provider about comprehensive biomarker testing

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USES